![Daqing Cai](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Daqing Cai
Direttore/Membro del Consiglio presso Beijing Shenogen Pharma Group Ltd.
Posizioni attive di Daqing Cai
Società | Posizione | Inizio | Fine |
---|---|---|---|
Beijing Shenogen Pharma Group Ltd.
![]() Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Direttore/Membro del Consiglio | - | - |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Daqing Cai
Precedenti posizioni note di Daqing Cai
Società | Posizione | Inizio | Fine |
---|---|---|---|
BIONANO GENOMICS, INC. | Direttore/Membro del Consiglio | 01/09/2014 | 21/08/2019 |
Independent Dir/Board Member | 01/09/2014 | 21/08/2019 | |
Legend Capital Co. Ltd.
![]() Legend Capital Co. Ltd. Investment ManagersFinance Legend Capital Co. Ltd (Legend Capital) is a private equity venture capital subsidiary of Legend Holdings Corp. founded in 2001 by Zhu Li Nan. The firm is headquartered in Beijing, China. | Corporate Officer/Principal | 01/10/2012 | 01/04/2018 |
Beijing Genomics Institute
![]() Beijing Genomics Institute BiotechnologyHealth Technology Part of BGI Genomics Co., Ltd., Beijing Genomics Institute develops science and technology services in the genomics field. The company is based in Shenzhen, China. | Direttore/Membro del Consiglio | 01/01/2014 | 01/01/2016 |
Direttore Finanziario/CFO | 01/01/2014 | 01/01/2016 | |
Indi Molecular, Inc.
![]() Indi Molecular, Inc. BiotechnologyHealth Technology Indi Molecular, Inc. is a life sciences company that develops a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. It offers products used by physicians and patients to manage complex and serious diseases like cancer, diabetes, and Alzheimer's. The company was founded by Michael Phelps, Albert A. Luderer, Leroy E. Hood, and Jim Heath in 2013 and is headquartered in Culver City, CA. | Direttore/Membro del Consiglio | - | - |
INNOVENT BIOLOGICS, INC. | Direttore/Membro del Consiglio | - | - |
AXONICS, INC. | Direttore/Membro del Consiglio | - | - |
Formazione di Daqing Cai
Yale University | Masters Business Admin |
University of California, Berkeley | Doctorate Degree |
University of Science & Technology of China | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 7 |
Cina | 5 |
Hong Kong | 2 |
Posizioni
Director/Board Member | 7 |
Independent Dir/Board Member | 1 |
Director of Finance/CFO | 1 |
Settori
Health Technology | 8 |
Consumer Services | 4 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
BIONANO GENOMICS, INC. | Health Technology |
INNOVENT BIOLOGICS, INC. | Health Technology |
AXONICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Legend Capital Co. Ltd.
![]() Legend Capital Co. Ltd. Investment ManagersFinance Legend Capital Co. Ltd (Legend Capital) is a private equity venture capital subsidiary of Legend Holdings Corp. founded in 2001 by Zhu Li Nan. The firm is headquartered in Beijing, China. | Finance |
Indi Molecular, Inc.
![]() Indi Molecular, Inc. BiotechnologyHealth Technology Indi Molecular, Inc. is a life sciences company that develops a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. It offers products used by physicians and patients to manage complex and serious diseases like cancer, diabetes, and Alzheimer's. The company was founded by Michael Phelps, Albert A. Luderer, Leroy E. Hood, and Jim Heath in 2013 and is headquartered in Culver City, CA. | Health Technology |
Beijing Genomics Institute
![]() Beijing Genomics Institute BiotechnologyHealth Technology Part of BGI Genomics Co., Ltd., Beijing Genomics Institute develops science and technology services in the genomics field. The company is based in Shenzhen, China. | Health Technology |
Beijing Shenogen Pharma Group Ltd.
![]() Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Health Technology |
Appia Bio, Inc.
![]() Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Health Technology |
- Borsa valori
- Insiders
- Daqing Cai
- Esperienza